Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DaveAu who wrote (7063)	3/28/2001 11:17:52 PM
From: Montana Wildhack	Read Replies (1) of 14101

Hi Dave, No. In light of no other input at the time I used a flat 45 in local currency for each market. I believe in the case of the UK though, there may be some synergy on the other end. I have harped on being the lowest cost alternative as a pricing strategy and I'm very pleased that we're here. Modelling pricing into each market is a near art form in that you need to balance a small group of components where not understanding one means shooting into the dark. Dilligent work has been going on in the background to understand this pricing strategy and the 16 pounds sterling came to light a week ago. Its critical to understand the UK setup with its small number of distributors and the government reimbursement strategy there. That's the 4th confirmation that the selling price will be 16 sterling - but it may be that the DII side of the model estimate I made could remain close to my estimate. Making a lot of money per unit is as senseless as selling a ton and making no profit. You have to balance all the components to maximize the realities of the target. I've heard some wild numbers on both ends as to estimates of our February shipment size and (as I think you and I discussed) all sorts of flavours on revenue recognition. It does seem confirmed to me that Rebecca understood her market and has developed a good strategy. Two more for her: Market launch March 26 as stated Lowest cost alternative to COX2 as stated I can't emphasize enough how much I don't give a d*mn about announcements concerning market entries and I'll make that really clear. Announcement of FDA approval and J&J deal - $35? EPS after 18 months in the US with a good strategy - $4+ The short termers can have their pops and my best wishes. I plan to own my $4 investment at triple digits as we enter and own the fungal market. Still the best looking candidate in my mind for our first billion dollar a year drug. (I know Mark, WF10 and I'm willing to be wrong in this). Wolf BTW - June - France, Germany among others. Bam! Black ink. And with that and other markets on the horizon you'd better expand that plant! Oh, you did.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next